VASH1 and neoplasm: However, contrary to this expectation, immunohistochemical analyses of pathological human sections have revealed that increased VASH1 immunostaining in ECs of tumor vessels is predictive of poor clinical outcome in multiple cancer types including NSCLC13, 14, 15, 16, 17, 18, 19, 20; an exception to this is renal cell carcinoma.21